A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)
This trial looks at a treatment for cancer of the oesophagus (the gullet or food pipe). The usual treatment is chemoradiotherapy, which pairs chemotherapy drugs with radiotherapy beams to destroy cancer cells. Researchers are testing whether adding an immunotherapy drug called pembrolizumab (also known as Keytruda) improves treatment results. Pembrolizumab works by helping your body's immune system recognise and attack cancer cells. In this study, half of the participants receive pembrolizumab alongside their standard chemoradiotherapy. The other half receive a dummy medicine (a placebo drip) with their standard treatment. A computer randomly decides who gets which treatment, and neither you nor your doctor will know which group you are in. Researchers will check if pembrolizumab helps people live longer, delays cancer return, and monitors any side effects that occur during treatment.
At a glance
What is this study about?
Cancer of the oesophagus affects the food pipe that connects your throat to your stomach. For many people, the main treatment is chemoradiotherapy, which combines chemotherapy medicines with radiotherapy to shrink and destroy tumours. While this standard approach can be effective, doctors are looking for ways to improve outcomes and stop the cancer from returning.
Pembrolizumab is a type of medicine called an immunotherapy. Instead of killing cancer cells directly like chemotherapy does, it works by 'taking the brakes off' your immune system. This allows your body's natural defences to recognise and fight cancer cells more effectively. Pembrolizumab is already used to treat several other types of cancer.
This trial is designed to see whether giving pembrolizumab alongside standard chemoradiotherapy works better than chemoradiotherapy on its own. To test this fairly, participants are split into two groups by chance. One group receives the active study medicine, while the other receives a harmless saline drip (placebo), alongside the usual cancer treatment. This helps doctors learn whether any benefits or side effects are truly caused by pembrolizumab.
Key takeaways
- Tests adding pembrolizumab (Keytruda) to standard chemoradiotherapy for oesophageal cancer.
- Aims to find out if this combination helps people live longer and keeps cancer away.
- All participants receive standard chemoradiotherapy; half also get pembrolizumab and half get a placebo.
- Open to adults aged 18 and older who are fit enough for chemoradiotherapy.
- Taking part is completely voluntary and you can leave at any time.
Who may be eligible?
This study is open to adults aged 18 and older who have been diagnosed with cancer of the oesophagus and are scheduled to receive chemoradiotherapy as their main treatment. Both men and women can join.
To take part, you need to be well enough to carry out daily activities and be able to receive standard chemotherapy and radiotherapy safely. The medical team will check your overall fitness and organ function, such as your heart, kidneys, and liver.
You might not be able to join if you have already had certain cancer treatments, if you have an active autoimmune disease, or if you take medicines that weaken your immune system. The study team will review your full medical history to confirm if joining is safe for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have been diagnosed with cancer of the oesophagus (food pipe).
- My doctor has recommended chemoradiotherapy as my main treatment.
- I am generally well enough to manage daily tasks and attend regular hospital visits.
- I do not have an active autoimmune condition or serious unmanaged medical problem.
What does participation involve?
If you take part, you will receive standard chemoradiotherapy along with either pembrolizumab or a placebo. The medicines are given as a drip into a vein at the hospital. Radiotherapy is given in short daily sessions over several weeks. You will visit the clinic regularly for treatment, blood tests, and health checks. You will also have routine scans (such as CT or PET scans) to see how the cancer is responding. After treatment ends, the doctors will continue to check on your health through regular hospital follow-up visits or telephone calls over several years.
Potential risks and benefits
Locations (10)
- —UnverifiedPortugal
- —UnverifiedEstonia
- —UnverifiedRomania
- —UnverifiedFrance
- —UnverifiedItaly
- —UnverifiedGermany
- —UnverifiedDenmark
- —UnverifiedBelgium
- —UnverifiedHungary
- —UnverifiedCzechia
Common questions
What is a placebo and why is it used?
A placebo is a harmless dummy treatment, like salt water, that looks identical to the real medicine. It is used so researchers can be sure that any changes in health are due to the study drug and not other factors.
Will I miss out on standard cancer care if I join?
No. Everyone in this trial receives the full, standard chemoradiotherapy treatment. The study medicine or placebo is given in addition to standard care.
Can I choose whether I receive pembrolizumab or the placebo?
No. A computer randomly puts participants into groups to ensure the study results are fair and unbiased. Neither you nor your doctor can choose the group.
How long will I be involved in the study?
Treatment typically lasts for several months, followed by follow-up checks and scans for a few years to see how you are doing.
What happens if I decide I want to stop?
You are free to leave the trial at any point. If you choose to stop, your doctors will switch you to the best available standard treatment options.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.